UBS Group
MIRA icon

UBS Group’s MIRA Pharmaceuticals MIRA Stock Holding History

UBS Group’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.91K Buy
6,456
+3,756
+139% +$4.71K ﹤0.01% 8641
2025
Q4 		$4.08K Buy
2,700
+2,484
+1,150% +$3.65K ﹤0.01% 8893
2025
Q3 		$294 Sell
216
-284
-57% -$412 ﹤0.01% 9757
2025
Q2 		$605 Buy
+500
New +$577 ﹤0.01% 9782
2024
Q3 		– Sell
-29,546
Closed -$18.8K – 9857
2024
Q2 		$18.8K Buy
29,546
+24,775
+519% +$20.4K ﹤0.01% 7340
2024
Q1 		$5.25K Buy
+4,771
New +$5.18K ﹤0.01% 7556
2023
Q4 		– Sell
-25
Closed -$116 – 9673
2023
Q3 		$116 Buy
+25
New +$143 ﹤0.01% 8849

Other funds holding MIRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group's MIRA Position: Q1 2026 in Review

UBS Group increased its MIRA Pharmaceuticals (MIRA) stake by 139% in Q1 2026, buying an estimated $4.71K and bringing the position to 6,456 shares worth $6.91K. The position accounts for ﹤0.01% of the portfolio, ranked #8641.

UBS Group first reported a position in MIRA in Q3 2023 and has held it in 7 quarters since. The position peaked at $18.8K in Q2 2024. 26 funds tracked by Wall St. Rank hold MIRA as of Q1 2026.

  • UBS Group held 6,456 shares of MIRA Pharmaceuticals worth $6.91K as of Q1 2026.
  • UBS Group bought 3,756 MIRA Pharmaceuticals shares in Q1 2026, an estimated $4.71K.
  • MIRA Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8641 holding.
  • UBS Group first reported a position in MIRA Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • UBS Group's MIRA Pharmaceuticals position peaked at $18.8K in Q2 2024.
  • 26 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.